← Leaderboards
Lawrence E Ostrowski
University Of North Carolina Chapel Hill
$7,659,247
Attributed
$7,659,247
Total exposure
6
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $673.1K · FY2005–23$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$7,659,247 · 6
By mechanism
R01$6,150,040 · 3
RC1$966,238 · 1
R21$395,149 · 1
R03$147,820 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of North Carolina Chapel Hill
Same institution · by research overlap
- Richard C Boucher$55,332,929
- David B Peden$24,843,616
- Scott H Donaldson$8,054,486
- Ken D McCarthy$12,379,286
- Michael R Knowles$33,731,453
Others in their field
Top investigators on “Cystic Fibrosis”
- John F Engelhardt · University Of Iowa$42,933,706
- Michael R Knowles · University Of North Carolina Chapel Hill$30,250,682
- David A Stoltz · University Of Iowa$25,455,359
- Joseph Zabner · University Of Iowa$25,382,103
- Paul B McCray · University Of Iowa$25,146,293
- Richard C Boucher · University Of North Carolina Chapel Hill$24,890,955
Research focus
Cystic FibrosisCiliaPrimary Ciliary DyskinesiasLung DiseasesMutationProteinsMucociliary ClearanceGenesPhenotypeRare DiseasesIn VivoBronchiectasisHuman TissueChronicEpithelial CellsMutateAffectDefense MechanismsNosePathogenesisNovel TherapeuticsOtitis MediaNitric OxideMucous Body Substance
Grant awards (22)
Functional Studies of Novel Genes Mutated in Primary Ciliary Dyskinesia II: Genotype to Phenotype$633,910
R01 · FY2023 · HL · contact PI
Functional Studies of Novel Genes Mutated in Primary Ciliary Dyskinesia II: Genotype to Phenotype$633,910
R01 · FY2022 · HL · contact PI
Functional Studies of Novel Genes Mutated in Primary Ciliary Dyskinesia II: Genotype to Phenotype$633,910
R01 · FY2021 · HL · contact PI
Functional Studies of Novel Genes Mutated in Primary Ciliary Dyskinesia II: Genotype to Phenotype$673,135
R01 · FY2020 · HL · contact PI
Functional Studies of Novel Genes Mutated in Primary Ciliary Dyskinesia$380,000
R01 · FY2017 · HL · contact PI
Functional Studies of Novel Genes Mutated in Primary Ciliary Dyskinesia$380,000
R01 · FY2016 · HL · contact PI
Functional Studies of Novel Genes Mutated in Primary Ciliary Dyskinesia$374,300
R01 · FY2015 · HL · contact PI
Functional Studies of Novel Genes Mutated in Primary Ciliary Dyskinesia$372,400
R01 · FY2014 · HL · contact PI
Functional Studies of Novel Genes Mutated in Primary Ciliary Dyskinesia$361,760
R01 · FY2013 · HL · contact PI
Pilot Studies of the Effect of Aging on Mucociliary Clearance$71,820
R03 · FY2013 · AG · contact PI
Pilot Studies of the Effect of Aging on Mucociliary Clearance$76,000
R03 · FY2012 · AG · contact PI
Pilot Studies of Gene Therapy for Primary Ciliary Dyskinesia$482,443
RC1 · FY2010 · HL · contact PI
Pilot Studies of Gene Therapy for Primary Ciliary Dyskinesia$483,795
RC1 · FY2009 · HL · contact PI
Conditional Deletion of Dnaic1 as a Model of Primary Ciliary Dyskinesia$212,649
R21 · FY2007 · HL · contact PI
Conditional Deletion of Dnaic1 as a Model of Primary Ciliary Dyskinesia$182,500
R21 · FY2006 · HL · contact PI
A Ciliated Cell-Specific Promoter for Gene Therapy of CF$291,000
R01 · FY2005 · HL
A Ciliated Cell-Specific Promoter for Gene Therapy of CF$291,000
R01 · FY2004 · HL
A Ciliated Cell-Specific Promoter for Gene Therapy of CF$291,000
R01 · FY2003 · HL
A Ciliated Cell-Specific Promoter for Gene Therapy of CF$291,000
R01 · FY2002 · HL
IDENTIFICATION OF BIOCHEMICAL ABNORMALITIES IN PCD CILIA$186,278
R01 · FY2002 · HL
IDENTIFICATION OF BIOCHEMICAL ABNORMALITIES IN PCD CILIA$180,852
R01 · FY2001 · HL
IDENTIFICATION OF BIOCHEMICAL ABNORMALITIES IN PCD CILIA$175,585
R01 · FY2000 · HL